Drug
Linafexor clinical trials
Also written CS0159.
Keep track of what changes. Save the linafexor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 11
Cascade Pharmaceuticals, Inc (9) · Shanghai Jiao Tong University School of Medicine (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses linafexor is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingPhase 3Cascade Pharmaceuticals, IncNCT07282353Written as 2mg CS0159
- Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DMNot yet recruitingNot applicableShanghai Jiao Tong University School of MedicineNCT07570810Written as CS0159
- Drug Interaction and Food Effect Study of CS0159CompletedPhase 1Cascade Pharmaceuticals, IncNCT07429331Written as CS0159 Tablet
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingPhase 2Cascade Pharmaceuticals, IncNCT05896124Written as 2mg CS0159
- CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)Active, not recruitingPhase 2Cascade Pharmaceuticals, IncNCT05896137Written as CS0159
- A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic InjuryCompletedPhase 1Cascade Pharmaceuticals, IncNCT06888115Written as CS0159
- Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DMCompletedNot applicableShanghai Jiao Tong University School of MedicineNCT06492330Written as CS0159
- Study of [14C]CS0159 in China Healthy SubjectsCompletedPhase 1Cascade Pharmaceuticals, IncNCT06098027Written as [14C]CS0159
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASHCompletedPhase 2Cascade Pharmaceuticals, IncNCT05591079Written as CS0159 (Linafexor)
- Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy SubjectsCompletedPhase 1Cascade Pharmaceuticals, IncNCT05624294Written as CS0159
- Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159CompletedPhase 1Cascade Pharmaceuticals, IncNCT05082779Written as CS0159